Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Niraparib
Synonyms
Therapy Description

Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Niraparib Zejula MK4827 PARP Inhibitor (Pan) 31 Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
IDH1 R132C cholangiocarcinoma no benefit Niraparib Preclinical - Patient cell culture Actionable In a preclinical study, cholangiocarcinoma patient-derived xenograft (PDX) cell lines harboring IDH1 R132C were insensitive to Zejula (niraparib) in culture (PMID: 36374558). 36374558
ARID1B Q127_Q131del IDH1 R132L cholangiocarcinoma no benefit Niraparib Preclinical - Patient cell culture Actionable In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Zejula (niraparib) in culture (PMID: 36374558). 36374558
PTEN negative prostate cancer not predictive Niraparib Phase I Actionable In a Phase I trial, negative PTEN IHC staining was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502). 23810788
RAD51C H192_R193delinsGG ovarian carcinoma resistant Niraparib Preclinical - Cell culture Actionable In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). 28588062
RAD51D K91Ifs*13 ovarian cancer sensitive Niraparib Preclinical - Cell culture Actionable In a preclinical study, Zejula (niraparib) inhibited viability of ovarian cancer cell lines expressing RAD51D K91Ifs*13 in culture (PMID: 38905575). 38905575
IDH1 R132H Advanced Solid Tumor sensitive Niraparib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839). 28148839
RAD51C R193L ovarian carcinoma resistant Niraparib Preclinical - Cell culture Actionable In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). 28588062
RAD51C R193W ovarian carcinoma resistant Niraparib Preclinical - Cell culture Actionable In a preclinical study, ovarian carcinoma cells expressing RAD51C R193W demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062). 28588062

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04221503 Phase II Niraparib Niraparib/TTFields in GBM Active, not recruiting USA 0
NCT04641247 Phase II Niraparib A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Active, not recruiting USA | ITA | ISR | FRA | ESP | DNK | CAN | AUT 0
NCT02925234 Phase II Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT04817956 Phase II Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) Recruiting NOR 0
NCT03088059 Phase II Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil Biomarker-based Study in R/M SCCHN (UPSTREAM) Active, not recruiting ITA | GBR | FRA | ESP | BEL 0
NCT03359850 Phase I Niraparib Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Completed USA 0
NCT04185831 Phase II Atezolizumab Niraparib Cobimetinib Everolimus A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT) Active, not recruiting SWE 0
NCT04030559 Phase II Niraparib Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Recruiting USA 0
NCT04240106 Phase II Niraparib Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) Completed ESP 0
NCT04080284 Phase II Niraparib Trial of Maintenance With Niraparib- Uterine Serous Carcinoma Recruiting USA 0
NCT03945721 Phase I Niraparib A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY) Active, not recruiting USA 0
NCT02354131 Phase Ib/II Niraparib Bevacizumab + Niraparib Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA) Completed USA | DNK 0
NCT04655183 Phase Ib/II Niraparib + VX-803 Niraparib Study of M4344 in Combination With Niraparib Withdrawn 0
NCT02354586 Phase II Niraparib A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Completed USA | CAN 0
NCT01905592 Phase III Niraparib A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO) Terminated USA | POL | NLD | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | CAN | BEL 1
NCT05615818 Phase III Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) Recruiting GBR | FRA | BEL 0
NCT05672095 Phase Ib/II Niraparib Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Not yet recruiting USA 0
NCT05718323 Phase II Niraparib Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE) Recruiting ROU | ITA | FRA | ESP | CHE 0
NCT06180356 Phase II Niraparib Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA) Recruiting ESP 0
NCT04915755 Phase III Niraparib Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) Active, not recruiting USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 6
NCT05169437 Phase II Niraparib Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO) Terminated USA 0
NCT05455424 Phase II Niraparib Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO) Active, not recruiting GBR 0
NCT06412120 FDA approved Niraparib Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Not yet recruiting USA 0
NCT05076513 Phase I Niraparib Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Recruiting USA 0
NCT03308942 Phase II Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Completed USA 0
NCT06077877 Phase Ib/II GSK4524101 + Niraparib GSK4524101 Niraparib A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors Recruiting USA | CAN 0
NCT03602859 Phase III Dostarlimab-gxly + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL 2
NCT03644342 Phase Ib/II Niraparib Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) Terminated USA 0
NCT02500901 Phase I Niraparib Enzalutamide Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) Terminated USA 0
NCT05442749 Phase II Niraparib Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) Withdrawn FRA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT04992013 Phase II Niraparib Niraparib in Tumors Metastatic to the CNS Recruiting USA 0
NCT03553004 Phase II Niraparib Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial Active, not recruiting USA 0
NCT04341181 Phase II Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) Recruiting DNK 0
NCT02655016 Phase III Niraparib A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting USA | SWE | POL | NOR | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL 2
NCT04037254 Phase II Niraparib Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer Active, not recruiting USA | CAN 0
NCT03329937 Phase I Niraparib Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment Completed USA 0
NCT05406700 Phase I Niraparib Niraparib In Recurrent IDH 1/2 Gliomas Recruiting USA 0
NCT03329001 Phase I Niraparib Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule Completed USA 0
NCT05523440 Phase II Bevacizumab + Niraparib Niraparib Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Recruiting USA 0
NCT06388733 Phase III Niraparib Temozolomide A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Recruiting USA 0
NCT04592237 Phase II Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Active, not recruiting USA 0
NCT04861181 FDA approved Niraparib NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) Recruiting FRA 0
NCT03840967 Phase II Niraparib A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Terminated USA 0
NCT05174455 Phase II Niraparib Niraparib for the Treatment of Leiomyosarcoma Withdrawn 0
NCT05990192 Phase II Niraparib SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO) Recruiting GBR 0
NCT05297864 Phase II Niraparib PARP Inhibition for Gliomas (PI-4G or pi4g) Terminated USA 0
NCT03601923 Phase II Niraparib Niraparib in Patients With Pancreatic Cancer Active, not recruiting USA 0
NCT03925350 Phase II Niraparib Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation Unknown status USA 0
NCT03891576 Phase II Niraparib Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton) Active, not recruiting ITA | DEU 0
NCT02854436 Phase II Niraparib An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Completed USA | SWE | NLD | ISR | GBR | FRA | ESP | DNK | CAN | BRA | BEL | AUS 3
NCT05961124 Phase II Niraparib Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer Recruiting CAN 0
NCT03598270 Phase III Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) Completed ITA | FRA | ESP | DEU | BEL 0
NCT04288687 Phase II Niraparib A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Completed USA 0
NCT05515575 Phase II Niraparib A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA Active, not recruiting USA 0
NCT06201234 Phase II Niraparib Elacestrant + Niraparib Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) Recruiting DEU 0
NCT01847274 Phase III Niraparib A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed USA | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT 0
NCT05238831 Phase II Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole SMMART Adaptive Clinical Treatment (ACT) Trial Withdrawn 0
NCT04584255 Phase II Dostarlimab-gxly + Niraparib Niraparib Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Recruiting USA 0
NCT03016338 Phase II Niraparib Study of Niraparib in Recurrent Endometrial Cancer Active, not recruiting CAN 0
NCT03651206 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Doxorubicin + Gemcitabine + Paclitaxel Niraparib Dostarlimab-gxly + Niraparib Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN) Active, not recruiting FRA 0


Additional content available in CKB BOOST